文献速递胃肠外科围术期管理与 ERAS

腹主动脉瘤初级保健患者的心血管风险预防与全因死亡率

Cardiovascular risk prevention and all-cause mortality in primary care patients with an abdominal aortic aneurysm.
PubMed 文献 · Br J Surg · 2016-10-05

结果显示他汀、抗血小板和降压药物的处方率均上升,且接受各治疗的患者5年生存率均优于未接受者。结论认为适当的心血管风险因素干预可显著降低腹主动脉瘤患者的长期死亡率,但英国仍有高达30%的患者未接受这些药物治疗。

要点

  • 腹主动脉瘤患者接受他汀、抗血小板或降压药物治疗与更好的5年生存率相关。
  • 英国约30%的腹主动脉瘤患者未接受这些心血管风险药物治疗。

核心结论

  • 适当的心血管风险因素干预可显著降低腹主动脉瘤患者的长期死亡率。
  • 英国目前高达30%的腹主动脉瘤患者未接受这些药物治疗。

研究设计与样本

  • 研究基于英国THIN全科医疗数据库2000至2012年的记录。
  • 采用G-computation公式并纳入时变协变量分析死亡进展。

主要发现

  • 调整后Kaplan-Meier曲线显示接受各治疗的患者5年生存率均更好。

临床怎么用

  • 对腹主动脉瘤患者应评估并管理心血管风险,考虑他汀、抗血小板和降压药物治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Perioperative mortality is low for patients undergoing abdominal aortic aneurysm (AAA) repair, but long-term survival remains poor. Although patients diagnosed with AAA have a significant burden of cardiovascular disease and associated risk factors, there is limited understanding of the contribution of cardiovascular risk management to long-term survival. METHODS: General practice records within The Health Improvement Network (THIN) were examined. Patients with a diagnosis of AAA and at least 1 year of registered medical history were identified from 2000 to 2012. Medical therapies for cardiovascular risk were classified as antiplatelet, statin or antihypertensive agents. Progression to death was investigated using the G-computation formula with time-dependent co-variables to account for differences in exposure to cardiovascular risk-modifying treatments and the confounding between exposure, co-morbidities and death. RESULTS: Some 12 485 patients had a recorded diagnosis of AAA. From 2000 to 2012, prescription of medications that modify cardiovascular risk increased: from 26·6 to 76·7 per cent for statins, from 56·5 to 73·9 per cent for antiplatelet agents and from 75·3 to 84·0 per cent for antihypertensive drugs. Adjusted Kaplan-Meier curves demonstrated a better 5-year survival rate in patients receiving statins (68·4 versus 42·2 per cent), antiplatelet agents (63·6 versus 39·7 per cent) or antihypertensive agents (61·5 versus 39·1 per cent), compared with rates in patients not receiving each therapy. CONCLUSION: Appropriate risk factor modification could significantly reduce long-term mortality in patients with AAA. In the UK, up to 30 per cent of patients are not currently receiving these medications.

来源:Br J Surg,查看原文。版权归原作者所有。

引用

  1. Bahia SS, Vidal-Diez A, Seshasai SR, et al. Cardiovascular risk prevention and all-cause mortality in primary care patients with an abdominal aortic aneurysm. Br J Surg. 2016. PMID: 27704527. doi:10.1002/bjs.10269

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。